{"transactions":[{"id":745879,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-06-08T20:14:03.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":23931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":23931,"derivative":{"exercise_price":15.67,"expiration_date":"2036-06-04","underlying":"Common Shares","underlying_shares":23931},"source":{"system":"sec-edgar","filing":"0001370348-26-000002","document":"wk-form4_1780949641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000137034826000002/wk-form4_1780949641.xml","form_type":"4"}},{"id":923410,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-03T15:00:08.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":53960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock."}],"balance_after":53960,"source":{"system":"sec-edgar","filing":"0001193125-26-034629","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526034629/ownership.xml","form_type":"4"}},{"id":989738,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-24T22:17:53.000Z","date":"2025-11-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":6039,"price":15.68,"value":94691.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":14592,"source":{"system":"sec-edgar","filing":"0001370348-25-000004","document":"wk-form4_1764022670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000137034825000004/wk-form4_1764022670.xml","form_type":"4"}},{"id":1144954,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-16T21:05:19.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":37485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest one year from date of grant."}],"balance_after":37485,"derivative":{"exercise_price":8.15,"expiration_date":"2035-05-16","underlying":"Common Shares","underlying_shares":37485},"source":{"system":"sec-edgar","filing":"0001600620-25-000077","document":"wk-form4_1747429513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000160062025000077/wk-form4_1747429513.xml","form_type":"4"}},{"id":1286300,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T22:30:25.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":35900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":35900,"derivative":{"exercise_price":1.7,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":35900},"source":{"system":"sec-edgar","filing":"0000950170-25-013756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000095017025013756/ownership.xml","form_type":"4/A","original_submission_date":"2025-02-03"}},{"id":1286299,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T22:30:25.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":17950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contigent right to receive one share of common stock."}],"balance_after":83770,"source":{"system":"sec-edgar","filing":"0000950170-25-013756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000095017025013756/ownership.xml","form_type":"4/A","original_submission_date":"2025-02-03"}},{"id":1288403,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-03T16:41:01.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":35900,"price":1.73,"value":62107.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":35900,"derivative":{"exercise_price":1.73,"expiration_date":"2035-01-30","underlying":"Common Stock","underlying_shares":35900},"source":{"system":"sec-edgar","filing":"0000950170-25-012101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000095017025012101/ownership.xml","form_type":"4"}},{"id":1288402,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T16:41:01.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":17950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were granted as restricted stock units which vest in full on January 30, 2026. Each restricted stock unit represents a contigent right to receive one share of common stock."}],"balance_after":83770,"source":{"system":"sec-edgar","filing":"0000950170-25-012101","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000095017025012101/ownership.xml","form_type":"4"}},{"id":1352409,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-11-25T21:33:38.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":31688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest one year from date of grant."}],"balance_after":31688,"derivative":{"exercise_price":8.24,"expiration_date":"2034-11-21","underlying":"Common Shares","underlying_shares":31688},"source":{"system":"sec-edgar","filing":"0001600620-24-000122","document":"wk-form4_1732570412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000160062024000122/wk-form4_1732570412.xml","form_type":"4"}},{"id":1352408,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:33:38.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":20631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant."}],"balance_after":20631,"source":{"system":"sec-edgar","filing":"0001600620-24-000122","document":"wk-form4_1732570412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000160062024000122/wk-form4_1732570412.xml","form_type":"4"}},{"id":1672780,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the \"Maximum Total Consideration\"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the \"Maximum Total Consideration\"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":64.14,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672779,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":7520},"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672778,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":27,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672777,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":20.54,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672776,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":15.72,"expiration_date":"2026-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672775,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the \"Converted Cash Award\"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672774,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4444,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units (\"RSUs\") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU."}],"balance_after":6808,"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1672773,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:54.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6021,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company (\"BMS\"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of January 23, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the \"Closing Consideration\") and (B) one contingent value right (a \"CVR\"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the \"Merger Consideration\"), without interest and subject to any withholding taxes."}],"balance_after":11252,"source":{"system":"sec-edgar","filing":"0001140361-24-003534","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000114036124003534/form4.xml","form_type":"4"}},{"id":1675836,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-20T02:03:27.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":83685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":83685,"derivative":{"exercise_price":2.09,"expiration_date":"2034-01-19","underlying":"Common Stock","underlying_shares":83685},"source":{"system":"sec-edgar","filing":"0001209191-24-001979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919124001979/doc4.xml","form_type":"4"}},{"id":1675835,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-20T02:03:27.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":13948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were granted as restricted stock units which vest in full on January 19, 2025."}],"balance_after":65820,"source":{"system":"sec-edgar","filing":"0001209191-24-001979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919124001979/doc4.xml","form_type":"4"}},{"id":1691307,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T23:37:24.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":6808,"price":58.75,"value":399970.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date."}],"balance_after":17273,"source":{"system":"sec-edgar","filing":"0001628280-24-000321","document":"wk-form4_1704325032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000162828024000321/wk-form4_1704325032.xml","form_type":"4"}},{"id":2047300,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2023-01-24T21:19:41.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":7520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":7520,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":7520},"source":{"system":"sec-edgar","filing":"0001214659-23-001048","document":"marketforms-58260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465923001048/marketforms-58260.xml","form_type":"4"}},{"id":2047299,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-24T21:19:41.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":4444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":10465,"source":{"system":"sec-edgar","filing":"0001214659-23-001048","document":"marketforms-58260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465923001048/marketforms-58260.xml","form_type":"4"}},{"id":2080349,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-20T22:20:58.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":77160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":77160,"derivative":{"exercise_price":2.74,"expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":77160},"source":{"system":"sec-edgar","filing":"0001209191-22-062188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919122062188/doc4.xml","form_type":"4"}},{"id":2080348,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-20T22:20:58.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":38580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were granted as restricted stock units which vest in full on December 16, 2023."}],"balance_after":51872,"source":{"system":"sec-edgar","filing":"0001209191-22-062188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919122062188/doc4.xml","form_type":"4"}},{"id":2175346,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.81,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175345,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.53,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175344,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.25,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175343,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.99,"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175342,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.1,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175341,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.19,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175340,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":28.24,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175339,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.69,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175338,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":19000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":10.84,"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175337,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6,"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2175336,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-24T20:17:54.000Z","date":"2022-08-22","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":6.23,"value":74760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation (\"Parent\"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a \"Share\"), and thereafter merged with and into the Issuer (the \"Merger\") effective as of August 22, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-029650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000089924322029650/doc4.xml","form_type":"4"}},{"id":2208763,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-07-12T20:36:35.000Z","date":"2022-07-08","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This is a cash exercise of options that vested and became exercisable on December 20, 2020."}],"balance_after":0,"derivative":{"exercise_price":3.93,"expiration_date":"2029-12-20","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-041988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122041988/doc4.xml","form_type":"4"}},{"id":2208762,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T20:36:35.000Z","date":"2022-07-08","kind":"exercise","acquired":true,"shares":12000,"price":3.93,"value":47160.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This is a cash exercise of options that vested and became exercisable on December 20, 2020."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-22-041988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122041988/doc4.xml","form_type":"4"}},{"id":2433468,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2022-01-18T23:20:46.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":3688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":3688,"derivative":{"exercise_price":124.31,"expiration_date":"2032-01-13","underlying":"Common Stock","underlying_shares":3688},"source":{"system":"sec-edgar","filing":"0001214659-22-000846","document":"marketforms-55082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465922000846/marketforms-55082.xml","form_type":"4"}},{"id":2433467,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-18T23:20:46.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":2546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":6021,"source":{"system":"sec-edgar","filing":"0001214659-22-000846","document":"marketforms-55082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465922000846/marketforms-55082.xml","form_type":"4"}},{"id":2435288,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T21:00:19.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on January 12, 2023 subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":30000,"derivative":{"exercise_price":4.81,"expiration_date":"2032-01-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-003404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000120919122003404/doc4.xml","form_type":"4"}},{"id":2460244,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-23T23:57:16.000Z","date":"2021-12-22","kind":"grant","acquired":true,"shares":20903,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":20903,"derivative":{"exercise_price":9.81,"expiration_date":"2031-12-22","underlying":"Common Stock","underlying_shares":20903},"source":{"system":"sec-edgar","filing":"0001209191-21-071169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919121071169/doc4.xml","form_type":"4"}},{"id":2460243,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T23:57:16.000Z","date":"2021-12-22","kind":"grant","acquired":true,"shares":10452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares were granted as restricted stock units which vest in full on December 22, 2022."}],"balance_after":13292,"source":{"system":"sec-edgar","filing":"0001209191-21-071169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919121071169/doc4.xml","form_type":"4"}},{"id":2460242,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-23T23:57:16.000Z","date":"2021-12-21","kind":"sale","acquired":false,"shares":250,"price":9.7277,"value":2431.925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. The shares were sold by Mr. Johnson to cover his estimated tax liability associated with the vesting of 750 restricted stock units (RSUs) on December 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The range of sales prices received was $9.625 to $9.845. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":2840,"source":{"system":"sec-edgar","filing":"0001209191-21-071169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919121071169/doc4.xml","form_type":"4"}},{"id":2561299,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-23T20:29:00.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":250,"price":12.2964,"value":3074.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. The shares were sold by Mr. Johnson to cover his estimated tax liability associated with the vesting of 750 restricted stock units (RSUs) on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The range of sales prices received was $12.15 to $12.40. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":3090,"source":{"system":"sec-edgar","filing":"0001209191-21-057419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919121057419/doc4.xml","form_type":"4"}},{"id":2659674,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T21:05:20.000Z","date":"2021-06-21","kind":"sale","acquired":false,"shares":250,"price":15.2024,"value":3800.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The range of sales prices received was $14.89 to $15.42. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":3340,"source":{"system":"sec-edgar","filing":"0001209191-21-042429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919121042429/doc4.xml","form_type":"4"}},{"id":2754951,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-07T21:04:58.000Z","date":"2021-04-06","kind":"sale","acquired":false,"shares":250,"price":17.2208,"value":4305.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The range of sales prices received was $16.98 to $17.48. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price."}],"balance_after":3590,"source":{"system":"sec-edgar","filing":"0001209191-21-025903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919121025903/doc4.xml","form_type":"4"}},{"id":2897426,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":0,"derivative":{"exercise_price":20.54,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897425,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":334,"price":214.7532,"value":71727.5688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $214.62 to $215.065.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3475,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897424,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":44,"price":213.62,"value":9399.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."}],"balance_after":3809,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897423,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":3372,"price":212.9748,"value":718151.0256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $212.52 to $213.34.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3853,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897422,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":4562,"price":211.9359,"value":966851.5758,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $211.40 to $212.25.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":7225,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897421,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":3183,"price":210.8088,"value":671004.4104,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $210.39 to $211.38.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":11787,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897420,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"sale","acquired":false,"shares":3505,"price":210.0056,"value":736069.628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $209.37 to $210.355.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":14970,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2897419,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-25T21:31:45.000Z","date":"2021-01-21","kind":"exercise","acquired":true,"shares":15000,"price":20.54,"value":308100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020."}],"balance_after":18475,"source":{"system":"sec-edgar","filing":"0001214659-21-000756","document":"marketforms-51235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000756/marketforms-51235.xml","form_type":"4"}},{"id":2901785,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2021-01-20T23:15:58.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":2155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":2155,"derivative":{"exercise_price":214.47,"expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":2155},"source":{"system":"sec-edgar","filing":"0001214659-21-000677","document":"marketforms-50980.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000677/marketforms-50980.xml","form_type":"4"}},{"id":2901784,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-20T23:15:58.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":1475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":3475,"source":{"system":"sec-edgar","filing":"0001214659-21-000677","document":"marketforms-50980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465921000677/marketforms-50980.xml","form_type":"4"}},{"id":2927321,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-31T21:01:51.000Z","date":"2020-12-29","kind":"purchase","acquired":true,"shares":3000,"price":17,"value":51000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired through the open market."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-20-065664","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000120919120065664/doc4.xml","form_type":"4"}},{"id":2933796,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-23T21:21:02.000Z","date":"2020-12-21","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":18000,"derivative":{"exercise_price":19.46,"expiration_date":"2030-12-21","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-20-065011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919120065011/doc4.xml","form_type":"4"}},{"id":2933795,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-23T21:21:02.000Z","date":"2020-12-21","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were granted as restricted stock units which vest in four equal quarterly installments beginning three months after the date of grant."}],"balance_after":3840,"source":{"system":"sec-edgar","filing":"0001209191-20-065011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919120065011/doc4.xml","form_type":"4"}},{"id":2947305,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-14T16:20:03.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years."}],"balance_after":30000,"derivative":{"exercise_price":4.53,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000920465-20-000163","document":"wf-form4_160798079024007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046520000163/wf-form4_160798079024007.xml","form_type":"4"}},{"id":2949856,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-10T21:04:12.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (\"FDA\") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":15000,"derivative":{"exercise_price":16.52,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-062684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000120919120062684/doc4.xml","form_type":"4"}},{"id":3172235,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2020-04-21T21:26:25.000Z","date":"2020-04-20","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":0,"derivative":{"exercise_price":25.84,"expiration_date":"2025-05-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001214659-20-003604","document":"marketforms-48601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465920003604/marketforms-48601.xml","form_type":"4"}},{"id":3172234,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-21T21:26:25.000Z","date":"2020-04-20","kind":"sale","acquired":false,"shares":15000,"price":93,"value":1395000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001214659-20-003604","document":"marketforms-48601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465920003604/marketforms-48601.xml","form_type":"4"}},{"id":3172233,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-21T21:26:25.000Z","date":"2020-04-20","kind":"exercise","acquired":true,"shares":15000,"price":25.84,"value":387600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0001214659-20-003604","document":"marketforms-48601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465920003604/marketforms-48601.xml","form_type":"4"}},{"id":3312787,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-13T16:17:50.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years."}],"balance_after":30000,"derivative":{"exercise_price":5.25,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000920465-20-000013","document":"wf-form4_157895025331000.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046520000013/wf-form4_157895025331000.xml","form_type":"4"}},{"id":3316045,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2020-01-08T01:27:55.000Z","date":"2020-01-03","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":4000,"derivative":{"exercise_price":113.2,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001214659-20-000191","document":"marketforms-47234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465920000191/marketforms-47234.xml","form_type":"4"}},{"id":3316044,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-08T01:27:55.000Z","date":"2020-01-03","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001214659-20-000191","document":"marketforms-47234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465920000191/marketforms-47234.xml","form_type":"4"}},{"id":3333109,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-23T21:24:08.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":25.02,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-19-061788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919119061788/doc4.xml","form_type":"4"}},{"id":3333017,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-23T16:08:54.000Z","date":"2019-12-20","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on December 20, 2020."}],"balance_after":12000,"derivative":{"exercise_price":3.93,"expiration_date":"2029-12-20","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000920465-19-000181","document":"wf-form4_157713531693251.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046519000181/wf-form4_157713531693251.xml","form_type":"4"}},{"id":3343451,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-12T23:20:33.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (\"FDA\") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":30.51,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-060277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000120919119060277/doc4.xml","form_type":"4"}},{"id":3681050,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2019-02-01T00:00:14.000Z","date":"2019-01-29","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":0,"derivative":{"exercise_price":3.65,"expiration_date":"2027-05-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001214659-19-000676","document":"marketforms-43887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000676/marketforms-43887.xml","form_type":"4"}},{"id":3681049,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2019-02-01T00:00:14.000Z","date":"2019-01-29","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the shares subject to the Option shall vest and become exercisable on September 4, 2014, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":0,"derivative":{"exercise_price":15.79,"expiration_date":"2023-11-07","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001214659-19-000676","document":"marketforms-43887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000676/marketforms-43887.xml","form_type":"4"}},{"id":3681048,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-01T00:00:14.000Z","date":"2019-01-29","kind":"sale","acquired":false,"shares":8525,"price":61.7984,"value":526831.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $61.44 to $62.37.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001214659-19-000676","document":"marketforms-43887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000676/marketforms-43887.xml","form_type":"4"}},{"id":3681047,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-01T00:00:14.000Z","date":"2019-01-29","kind":"sale","acquired":false,"shares":8475,"price":61.114,"value":517941.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $60.43 to $61.42.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":8525,"source":{"system":"sec-edgar","filing":"0001214659-19-000676","document":"marketforms-43887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000676/marketforms-43887.xml","form_type":"4"}},{"id":3681046,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-01T00:00:14.000Z","date":"2019-01-29","kind":"exercise","acquired":true,"shares":10000,"price":3.65,"value":36500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0001214659-19-000676","document":"marketforms-43887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000676/marketforms-43887.xml","form_type":"4"}},{"id":3681045,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-01T00:00:14.000Z","date":"2019-01-29","kind":"exercise","acquired":true,"shares":7000,"price":15.79,"value":110530.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001214659-19-000676","document":"marketforms-43887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000676/marketforms-43887.xml","form_type":"4"}},{"id":3685838,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-28T12:54:10.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 23, 2020."}],"balance_after":12000,"derivative":{"exercise_price":5.99,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000920465-19-000024","document":"wf-form4_154869803331636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046519000024/wf-form4_154869803331636.xml","form_type":"4"}},{"id":3690488,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-01-23T00:00:29.000Z","date":"2019-01-17","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":11000,"derivative":{"exercise_price":64.14,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001214659-19-000455","document":"marketforms-43762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465919000455/marketforms-43762.xml","form_type":"4"}},{"id":3707689,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T01:07:58.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":12500,"derivative":{"exercise_price":14.08,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-001520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000120919119001520/doc4.xml","form_type":"4"}},{"id":3728044,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-19T01:05:12.000Z","date":"2018-12-15","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":21000,"derivative":{"exercise_price":24.97,"expiration_date":"2028-12-15","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-18-063346","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919118063346/doc4.xml","form_type":"4"}},{"id":4093535,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-01-22T23:00:25.000Z","date":"2018-01-18","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":27,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001214659-18-000583","document":"marketforms-40825.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000121465918000583/marketforms-40825.xml","form_type":"4"}},{"id":4106795,"issuer":{"id":132524,"kind":"organization","name":"Odonate Therapeutics, Inc.","symbol":"ODT"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-05T01:54:14.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on January 2, 2019."}],"balance_after":12500,"derivative":{"exercise_price":24.73,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-002270","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000120919118002270/doc4.xml","form_type":"4"}},{"id":4125519,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-20T21:17:06.000Z","date":"2017-12-18","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":21000,"derivative":{"exercise_price":17,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-17-066632","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919117066632/doc4.xml","form_type":"4"}},{"id":4133863,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-13T21:06:48.000Z","date":"2017-12-11","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on December 11, 2018."}],"balance_after":10000,"derivative":{"exercise_price":28.1,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000920465-17-000081","document":"wf-form4_151321719471634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046517000081/wf-form4_151321719471634.xml","form_type":"4"}},{"id":4311425,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-05-19T22:04:47.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":3.65,"expiration_date":"2027-05-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001190725-17-000126","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370348/000119072517000126/edgardoc.xml","form_type":"4"}},{"id":4496928,"issuer":{"id":124310,"kind":"organization","name":"LA JOLLA PHARMACEUTICAL CO","symbol":"LJPC"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-06T18:22:50.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 4, 2018."}],"balance_after":10000,"derivative":{"exercise_price":19.19,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000920465-17-000015","document":"wf-form4_148374495798908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920465/000092046517000015/wf-form4_148374495798908.xml","form_type":"4"}},{"id":4512839,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-23T21:06:39.000Z","date":"2016-12-21","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant."}],"balance_after":21000,"derivative":{"exercise_price":13,"expiration_date":"2026-12-21","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-16-156663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919116156663/doc4.xml","form_type":"4"}},{"id":4582949,"issuer":{"id":7133,"kind":"organization","name":"HERON THERAPEUTICS, INC. /DE/"},"owners":[{"id":40405,"kind":"person","name":"Johnson Craig A","position":1,"cik":"0001370348","reported_name":"Johnson Craig A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-08T01:01:26.000Z","date":"2016-10-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":16.83,"exercise_date":"2017-10-07","expiration_date":"2026-10-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-16-145484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818033/000120919116145484/doc4.xml","form_type":"4"}}]}